Table 4 Mobilization therapy and cell characteristics in patients with newly-diagnosed, previously untreated multiple myeloma enrolled in phase I study of siltuximab in combination with RVD before ASCT (N=9)
Patient number | Mobilization regimen | Number of sessions needed to harvest cells | Total nucleated cells collected (e8/kg) | Total stem cells (CD34+) collected (e6/kg) | Days between completion of the last treatment cycle and ASCT | Day of engraftment post ASCT | Disease progression | Progression-free survival (days) |
|---|---|---|---|---|---|---|---|---|
2 | Plerixafor/G-CSF | 6 | 8.01 | 4.16 | 39 | 12 | N | 862 |
3 | Plerixafor/G-CSF | 6 | 8.77 | 4.55 | 43 | 12 | N | 811 |
4 | Cyclophosphamide/G-CSF | 1 | 3.69 | 19.22 | 64 | 11 | N | 757 |
5 | G-CSF | 5 | 6.42 | 2.88 | 88 | 11 | N | 736 |
7 | G-CSF | 1 | 3.37 | 5.36 | 56 | 11 | N | 725 |
8 | Modified CVAD/G-CSF | 1 | 3.49 | 9.21 | 47 | 11 | N | 548 |
9 | Plerixafor/G-CSF | 5 | 8.46 | 3.46 | 46 | 11 | N | 717 |
10 | G-CSF | 5 | 9.24 | 4.05 | 39 | 12 | N | 203 |
11 | Plerixafor/G-CSF | 2 | 5.92 | 4.08 | 52 | 11 | N | 533 |
